{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T04:48:00Z","timestamp":1789274880459,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Suzhou Health Talents Training Project","award":["GSWS2019002"],"award-info":[{"award-number":["GSWS2019002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00210-020-02009-7","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T10:21:46Z","timestamp":1604312506000},"page":"819-828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials"],"prefix":"10.1007","volume":"394","author":[{"given":"Bixi","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiran","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7342-0845","authenticated-orcid":false,"given":"Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"issue":"11","key":"2009_CR1","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1212\/01.wnl.0000325565.63526.d2","volume":"71","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Lipton RB (2008) Clinical course in migraine: conceptualizing migraine transformation. Neurology 71(11):848\u2013855. https:\/\/doi.org\/10.1212\/01.wnl.0000325565.63526.d2","journal-title":"Neurology"},{"issue":"11","key":"2009_CR2","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/s1474-4422(15)00249-5","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB (2015a) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14(11):1081\u20131090. https:\/\/doi.org\/10.1016\/s1474-4422(15)00249-5","journal-title":"Lancet Neurol"},{"issue":"11","key":"2009_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(15)00245-8","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD (2015b) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14(11):1091\u20131100. https:\/\/doi.org\/10.1016\/S1474-4422(15)00245-8","journal-title":"Lancet Neurol"},{"issue":"8","key":"2009_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/14737175.2019.1614742","volume":"19","author":"ME Bigal","year":"2019","unstructured":"Bigal ME, Walter S, Rapoport AM (2019) Fremanezumab as a preventive treatment for episodic and chronic migraine. Expert Rev Neurother 19(8):719\u2013728. https:\/\/doi.org\/10.1080\/14737175.2019.1614742","journal-title":"Expert Rev Neurother"},{"key":"2009_CR5","doi-asserted-by":"publisher","unstructured":"Bixi Gao NS, Yang Y, Sun Y, Chen M, Chen Z, Wang Z (2020) Safety and efficacy of fremanezumab for the prevention of migraine: a meta-analysis from randomized controlled trials. Front Neurol 11. https:\/\/doi.org\/10.3389\/fneur.2020.00435","DOI":"10.3389\/fneur.2020.00435"},{"issue":"4","key":"2009_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, Wilcox TK, Kawata AK, Lipton RB (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 53(4):644\u2013655. https:\/\/doi.org\/10.1111\/head.12055","journal-title":"Headache"},{"issue":"11","key":"2009_CR7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1177\/0333102413477736","volume":"33","author":"DC Buse","year":"2013","unstructured":"Buse DC, Lipton RB (2013) Global perspectives on the burden of episodic and chronic migraine. Cephalalgia 33(11):885\u2013890. https:\/\/doi.org\/10.1177\/0333102413477736","journal-title":"Cephalalgia"},{"key":"2009_CR8","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.mayocp.2016.02.013","volume":"91","author":"DC Buse","year":"2016","unstructured":"Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A, Lipton RB (2016) Impact of migraine on the family: perspectives of people with migraine and their spouse\/domestic partner in the CaMEO study. Mayo Clin Proc 91:596\u2013611. https:\/\/doi.org\/10.1016\/j.mayocp.2016.02.013","journal-title":"Mayo Clin Proc"},{"issue":"13","key":"2009_CR9","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1177\/0333102418771376","volume":"38","author":"O Cohen-Barak","year":"2018","unstructured":"Cohen-Barak O, Weiss S, Rasamoelisolo M, Faulhaber N, Yeung PP, Loupe PS, Yoon E, Gandhi MD, Spiegelstein O, Aycardi E (2018) A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects. Cephalalgia 38(13):1960\u20131971. https:\/\/doi.org\/10.1177\/0333102418771376","journal-title":"Cephalalgia"},{"issue":"10100","key":"2009_CR10","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"GBD Disease","year":"2017","unstructured":"Disease GBD, Injury I, Prevalence C (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(10100):1211\u20131259. https:\/\/doi.org\/10.1016\/S0140-6736(17)32154-2","journal-title":"Lancet"},{"issue":"19","key":"2009_CR11","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E (2018) Effect of Fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999\u20132008. https:\/\/doi.org\/10.1001\/jama.2018.4853","journal-title":"JAMA"},{"key":"2009_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2147\/NDT.S33769","volume":"9","author":"E Estemalik","year":"2013","unstructured":"Estemalik E, Tepper S (2013) Preventive treatment in migraine and the new US guidelines. Neuropsychiatr Dis Treat 9:709\u2013720. https:\/\/doi.org\/10.2147\/NDT.S33769","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2009_CR13","doi-asserted-by":"publisher","first-page":"e748","DOI":"10.1016\/j.wneu.2017.10.075","volume":"109","author":"E Fakharian","year":"2018","unstructured":"Fakharian E, Abedzadeh-Kalahroudi M, Atoof F (2018) Effect of tranexamic acid on prevention of hemorrhagic mass growth in patients with traumatic brain injury. World Neurosurg 109:e748\u2013e753. https:\/\/doi.org\/10.1016\/j.wneu.2017.10.075","journal-title":"World Neurosurg"},{"issue":"10203","key":"2009_CR14","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, Mueller M, Ahn AH, Schwartz YC, Grozinski-Wolff M, Janka L, Ashina M (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394(10203):1030\u20131040. https:\/\/doi.org\/10.1016\/S0140-6736(19)31946-4","journal-title":"Lancet"},{"issue":"2","key":"2009_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S (2017) Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 97(2):553\u2013622. https:\/\/doi.org\/10.1152\/physrev.00034.2015","journal-title":"Physiol Rev"},{"issue":"9","key":"2009_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache S","year":"2013","unstructured":"Headache Classification Committee of the International Headache S (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33(9):629\u2013808. https:\/\/doi.org\/10.1177\/0333102413485658","journal-title":"Cephalalgia"},{"issue":"17","key":"2009_CR17","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s40265-018-1004-5","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy SM (2018) Fremanezumab: first global approval. Drugs 78(17):1829\u20131834. https:\/\/doi.org\/10.1007\/s40265-018-1004-5","journal-title":"Drugs"},{"issue":"5","key":"2009_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, Group AA (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68(5):343\u2013349. https:\/\/doi.org\/10.1212\/01.wnl.0000252808.97649.21","journal-title":"Neurology"},{"issue":"9","key":"2009_CR19","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/head.13407","volume":"58","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Munjal S, Alam A, Buse DC, Fanning KM, Reed ML, Schwedt TJ, Dodick DW (2018) Migraine in America Symptoms and Treatment (MAST) study: baseline study methods, treatment patterns, and gender differences. Headache 58(9):1408\u20131426. https:\/\/doi.org\/10.1111\/head.13407","journal-title":"Headache"},{"issue":"12","key":"2009_CR20","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1080\/14712598.2019.1671350","volume":"19","author":"B Raffaelli","year":"2019","unstructured":"Raffaelli B, Neeb L, Reuter U (2019) Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther 19(12):1307\u20131317. https:\/\/doi.org\/10.1080\/14712598.2019.1671350","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"2009_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20(1):6. https:\/\/doi.org\/10.1186\/s10194-018-0955-y","journal-title":"J Headache Pain"},{"issue":"11","key":"2009_CR22","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40263-013-0081-y","volume":"27","author":"JR Saper","year":"2013","unstructured":"Saper JR, Da Silva AN (2013) Medication overuse headache: history, features, prevention and management strategies. CNS Drugs 27(11):867\u2013877. https:\/\/doi.org\/10.1007\/s40263-013-0081-y","journal-title":"CNS Drugs"},{"issue":"22","key":"2009_CR23","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa1709038","journal-title":"N Engl J Med"},{"issue":"6","key":"2009_CR24","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/head.13534","volume":"59","author":"SD Silberstein","year":"2019","unstructured":"Silberstein SD, McAllister P, Ning X, Faulhaber N, Lang N, Yeung P, Schiemann J, Aycardi E, Cohen JM, Janka L, Yang R (2019) Safety and tolerability of fremanezumab for the prevention of migraine: a pooled analysis of phases 2b and 3 clinical trials. Headache 59(6):880\u2013890. https:\/\/doi.org\/10.1111\/head.13534","journal-title":"Headache"},{"issue":"Suppl 3","key":"2009_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/head.13379","volume":"58","author":"SJ Tepper","year":"2018","unstructured":"Tepper SJ (2018) History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment. Headache 58(Suppl 3):238\u2013275. https:\/\/doi.org\/10.1111\/head.13379","journal-title":"Headache"},{"issue":"3","key":"2009_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11916-015-0476-1","volume":"19","author":"S Walter","year":"2015","unstructured":"Walter S, Bigal ME (2015) TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine. Curr Pain Headache Rep 19(3):6. https:\/\/doi.org\/10.1007\/s11916-015-0476-1","journal-title":"Curr Pain Headache Rep"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-020-02009-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-020-02009-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-020-02009-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T10:10:31Z","timestamp":1617012631000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-020-02009-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["2009"],"URL":"https:\/\/doi.org\/10.1007\/s00210-020-02009-7","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"4 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing inter.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}